Guardant Health, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Guardant Health (GH) director Musa Tariq filed a notice to sell 116 shares of common stock, valued at $20,300, under Rule 144. The shares come from equity compensation following a restricted stock lapse. Tariq has sold GH stock multiple times in the past three months, totaling hundreds of thousands in proceeds.
Guardant Health (GH) director Steve Krognes filed a Rule 144 notice to sell 6,674 shares, valued at $1.17M, acquired as equity compensation. The sale is expected to occur around September 16, 2026, with 134.2M shares outstanding.
ARK ETFs bought 9,070 shares of Guardant Health (GH) for $1.52M and 9,037 shares of AeroVironment (AVAV) for $1.39M. They sold 25,964 shares of Iridium (IRDM) for $1.2M, 313 shares of Teledyne (TDY) for $186,895, and 294 shares of Alphabet (GOOGL) for $102,720. These moves align with ARK's strategy of portfolio recalibration.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning GH (Guardant Health, Inc.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 2 bearish.
Recent GH coverage spans financial news, regulation and earnings.
In the last 30 days, GH insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($7.0M). The most active reporter was Talasaz AmirAli, Co-Chief Executive Officer, with 3 filings.
A small insider sale that may signal slight negative sentiment but unlikely to move the stock materially.
Potential dilution and insider selling pressure may weigh on the stock.
Potential short-term price support for Guardant Health.
The insider sale may exert modest downward pressure on GH stock.
Earnings beat and strong growth drive bullish outlook.
AlphAI scores every news story that mentions GH with an AI model for sentiment and relevance, and aggregates insider trades from Guardant Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Guardant Health (GH) director Musa Tariq filed a notice to sell 116 shares of common stock, valued at $20,300, under Rule 144. The shares come from equity compensation following a restricted stock lapse. Tariq has sold GH stock multiple times in the past three months, totaling hundreds of thousands in proceeds.
1 min readGuardant Health (GH) director Steve Krognes filed a Rule 144 notice to sell 6,674 shares, valued at $1.17M, acquired as equity compensation. The sale is expected to occur around September 16, 2026, with 134.2M shares outstanding.
1 min readARK ETFs bought 9,070 shares of Guardant Health (GH) for $1.52M and 9,037 shares of AeroVironment (AVAV) for $1.39M. They sold 25,964 shares of Iridium (IRDM) for $1.2M, 313 shares of Teledyne (TDY) for $186,895, and 294 shares of Alphabet (GOOGL) for $102,720. These moves align with ARK's strategy of portfolio recalibration.
2 min readGuardant Health officer Darya Chudova filed a Rule 144 notice to sell 7,738 shares, valued at $1.38M, acquired via equity compensation. The sale is planned for after September 15, 2026, with shares acquired between March 1, 2025, and July 1, 2026. Guardant Health has 134,196,170 shares outstanding.
1 min readGuardant Health Inc. (GH) hit a 52-week high of $176.68, up 216.17% in a year. Q2 revenue grew 44% to $335M, beating expectations. Analysts raised price targets, with Stifel at $180 and TD Cowen at $210, both maintaining Buy ratings. Positive outlook driven by healthcare advancements and strong product performance.
2 min readKalia Kumud (Chief Information Officer) sold 4,000 shares of Guardant Health, Inc. (GH) at $158.05 ($0.63M total) on 2026-09-11.
1 min readGuardant Health (GH) announced its Shield blood test for colorectal cancer screening will be covered by EviCore by Evernorth, a Cigna-owned company, starting January 1, 2027. This expands coverage to approximately 94 million adults aged 45 and older, according to the company. The test is also included in guidelines from the American Cancer Society and the National Comprehensive Cancer Network.
2 min readGuardant Health (GH) announced FDA approval for Guardant360 CDx as a companion diagnostic to identify breast cancer patients with ESR1 mutations, enabling early treatment with AstraZeneca's camizestrant. This is the first FDA-approved liquid biopsy CDx for longitudinal breast cancer testing. GH shares closed at $161.41, up 0.23%.
1 min readGuardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.
2 min readGuardant Health (GH) was ordered to pay $245.2M for patent infringement, with a 6% royalty on US sales of 11 products until 2033. The company plans to appeal, noting current versions of Reveal and Shield are excluded. The judgment includes $83.4M in damages, $19.5M in supplemental damages, $119.4M in royalties, and $22.9M in interest.
2 min read
